| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Foralumab (anti-CD3E)
CAS:946415-64-1
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14214
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Foralumab
CAS:946415-64-1
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Foralumab
CAS:946415-64-1
Purity:95% Package:1mg/RMB 993;5mg/RMB 3190;10mg/RMB 5430
|
|
| | Foralumab Basic information |
| Product Name: | Foralumab | | Synonyms: | Foralumab;Research Grade Foralumab(DHC27705);Research Grade Foralumab;Foralumab (anti-CD3E) | | CAS: | 946415-64-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Foralumab Structure]() |
| | Foralumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Foralumab Usage And Synthesis |
| Uses | Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells[1]. | | in vivo | Foralumab (NI-0401; 0.6-250 μg; p.o.; daily, for 5 d) delays the rejection of B6Rag2?/? skin grafted onto the humanized mice[1].
Foralumab (0.6-250 μg; p.o. and i.h.; daily, for 5 d) prevents skin xenograft rejection in mice with human immune systems[1].
Foralumab (1-15 μg; p.o.; daily, for 5 d) has good bioavailability of intragastric in humanized mice[1].
| Animal Model: | Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1] | | Dosage: | 15 μg | | Administration: | Oral administration; daily, for 5 days and weekly dosing | | Result: | Showed robust protection against graft rejection and prolongs graft survival.
Reduced proliferation of CD8+ T cells and reduced release of TNF.
Increased the concentration of IL-10.
|
| Animal Model: | Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1] | | Dosage: | 1, 5, 15, 50, and 250 μg (p.o.), 0.6 mg/kg (i.h.) | | Administration: | Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing | | Result: | Had tolerant to autologous skin grafts in humanized mice. |
| Animal Model: | Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1] | | Dosage: | 0, 5, 10, and 15 μg | | Administration: | Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing | | Result: | Increased human Ig on the surface of CD4+ and CD8+ T cells.
Had free mAb in the serum of mice
|
| | References | [1] Ogura M, et, al. Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. Clin Immunol. 2017 Oct;183:240-246. DOI:10.1016/j.clim.2017.07.005 |
| | Foralumab Preparation Products And Raw materials |
|